Abstract
The assessment of the gender and age-specific seroprevalence of human papillomavirus (HPV) is essential for planning of HPV vaccine implementation into the preventive programs. In this study, we aimed to determine the age-specific seroprevalence of HPV-16 and 18 in both males and females in Tehran, Iran. Three hundred and seventy-eight women (10–35 years) and 162 men (10–25 years) from Tehran, Iran, were enrolled. Anti-HPV IgG antibodies against HPV-16 and HPV-18 were detected by ELISA using papillomavirus type 16 and 18 L1-capsids as antigen. HPV-16 antibody was detected in 15.6 and 13.6% of women and men, respectively. Antibody against HPV-18 was found positive in 12.7 and 8% of women and men, respectively. The highest seroprevalence of HPV-16 and 18 were seen in women aged 26–30 years (22.2 and 19.4%, respectively), and the lowest HPV-16 and 18 seropositivity rates were seen in males and females aged 10–15 years (9.3 and 1.9%, respectively). In our cohort of study, in males, both anti-HPV-16 and 18 increased after age 15 years, peaking in men aged 21–25 years. In women, both HPV-16 and 18 seropositivity increased after 15 years, declined at 21–25 years, peaked in women aged 26–30 years and again decreased after 30 years. Our data showed increasing exposure rate to high-risk HPV vaccine types in our studied population over 15 years of age. In order to prevent the HPV-related cancers, implementation of HPV vaccine into the national immunization program in Iran and vaccination of females and males less than 15 years of age are suggested.
Similar content being viewed by others
References
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijder PJF, Meijer CJLM (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527
Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D (2009) Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9:347–356
Parkin DM, Bray F (2006) Chapter 2: the burden of HPV-related cancers. Vaccine 24(S3):11–25
Balanda M, Quiero A, Espinoza G, Martín HS, Rojas G, Ramírez E (2016) Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014–2015. Med Microbiol Immunol [Epub ahead of print]
Centers for Disease Control and Prevention Genital HPV Infection—CDC Fact Sheet. 2009. http://www.cdc.gov/std/HPV/STDFact-HPV.htm. Accessed 14 May 2012
Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S (2016) ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary Report 7 October 2016 [data downloaded at 5 November 2016]
Bodelon C, Untereiner ME, Machiela MJ, Vinokurova S, Wentzensen N (2016) Genomic characterization of viral integration sites in HPV-related cancers. Int J Cancer 139(9):2001–2011
Di Giuseppe G, Abbate R, Liguori G, Albano L, Angelillo IF (2008) Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Br J Cancer 99:225–229
Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S (2013) Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 31(Suppl 7):H59–H70
Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME (1994) Persistence of type specific human papillomavirus infection among cytologically normal women. J Infect Dis 169:235–240
Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365–1371
Schulze MH, Völker FM, Lugert R, Cooper P, Hasenclever K, Groß U, Pfister H, Silling S (2016) High prevalence of human papillomaviruses in Ghanaian pregnant women. Med Microbiol Immunol [Epub ahead of print]
Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958–964
Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 3:24–33
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muñoz J, Bosch FX, de Sanjosé S, Castellsagué X (2016) ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Iran. Summary Report 2016-02-26 [data downloaded at 5 November 2016]
Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R (2015) Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: implications for screening and vaccination. J Med Virol 87(2):287–295
Schiffman M, Safaeian M, Wentzensen N (2009) The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis 36:675–679
Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109(2 Suppl):S15–S21
Frazer IH (2009) Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384(2):410–414
Franceschi S, Baussano I (2014) Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era. J Infect Dis 210(4):507–509
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278
Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S (2003) Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 103:413–421
Ji J, Sun HK, Smith JS, Wang H, Esser MT, Hu S, Pretorius RG, Chen W, Belinson JL, Qiao YL (2012) Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women. BMC Infect Dis 12:137
Chen CJ, Viscidi RP, Chuang CH, Huang YC, Chiu CH, Lin TY (2007) Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. J Clin Virol 38(2):126–130
Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PJ, Meijer CJ, Franceschi S, Pawlita M (2008) Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 17:1731–1738
Vaccarella S, Franceschi S, Clifford GM, Touzé A, Hsu CC, de Sanjosé S, Pham TH, Nguyen TH, Matos E, Shin HR, Sukvirach S, Thomas JO, Boursaghin L, Gaitan J, Snijders PJ, Meijer CJ, Muñoz N, Herrero R, Coursaget P, IARC HPV Prevalence Surveys Study Group (2010) Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 19(9):2379–2388
Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A, Costa Rican Vaccine Trial Group (2010) Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102(21):1653–1662
Thompson DL, Douglas JM Jr, Foster M, Hagensee ME, Diguiseppi C, Barón AE, Cameron JE, Spencer TC, Zenilman J, Malotte CK, Bolan G, Kamb ML, Peterman TA, Project RESPECT Study Group (2004) Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 190(9):1563–1574
Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER (2009) Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 200(7):1059–1067
Dunne EF, Nielson CM, Hagensee ME, Papenfuss MR, Harris RB, Herrel N, Gourlie J, Abrahamsen M, Markowitz LE, Giuliano AR (2009) HPV 6/11, 16, 18 seroprevalence in men in two US cities. Sex Transm Dis 36(11):671–674
Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat NB (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197:279–282
Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazcano-Ponce E, da Silva RJ, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Stockwell HG, Giuliano AR (2011) Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev 20(5):990–1002
Lu B, Hagensee ME, Lee JH, Wu Y, Stockwell HG, Nielson CM, Abrahamsen M, Papenfuss M, Harris RB, Giuliano AR (2010) Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev 19(2):511–516
Slavinsky J, Kissinger P, Burger L, Boley A, DiCarlo RP (2001) Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 12:516–523
Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186:1396–1402
Malary M, Moosazadeh M, Hamzehgardeshi Z, Afshari M, Moghaddasifar I, Afsharimoghaddam A (2016) The prevalence of cervical human papillomavirus infection and the most at-risk genotypes among iranian healthy women: a systematic review and meta-analysis. Int J Prev Med 4(7):70
Salehi-Vaziri M, Sadeghi F, Bokharaei-Salim F, Younesi S, Alinaghi S, Monavari SH, Keyvani H (2015) The prevalence and genotype distribution of human papillomavirus in the genital tract of males in Iran. Jundishapur J Microbiol 8(12):e21912
Jalilvand S, Shoja Z, Hamkar R (2014) Human papillomavirus burden in different cancers in Iran: a systematic assessment. Asian Pac J Cancer Prev 15(17):7029–7035
Acknowledgements
The authors are grateful to Pasteur institute of Iran for financial support of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aghakhani, A., Mamishi, S., Sabeti, S. et al. Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran. Med Microbiol Immunol 206, 105–110 (2017). https://doi.org/10.1007/s00430-016-0487-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00430-016-0487-5